Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PCVX | +34.44% | +2.65% | −2.50% | +9.02% | +10.85% | +8.37% | +38.61% | +30.29% | +165.09% | +137.12% |
| DAOL-GIHEALTH | +0.59% | +2.18% | +4.84% | +0.25% | −4.97% | +6.10% | +3.92% | −0.91% | −42.59% | −45.65% |
| SCBIHEALTH(E) | +12.60% | +3.34% | +6.78% | +8.27% | +11.10% | +23.33% | +17.20% | +28.90% | −45.60% | −51.31% |
| SCBRMGHC | +10.74% | +2.25% | +5.00% | +6.38% | +3.73% | +14.65% | +20.10% | +47.97% | +22.97% | +24.53% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes PCVX: money market or bond funds, or no holdings data yet
| SCBIHEALTH(E) | SCBRMGHC | |
|---|---|---|
| Held by both | ||
 Eli Lilly and Co | 9.59% | 9.70% |
 ABBVIE | 6.48% | 4.98% |
 AstraZeneca | 5.99% | 3.74% |
 Thermo Fisher | 4.12% | 3.38% |
 argenx | 3.12% | 2.47% |
 Merck & | 6.49% | 2.37% |
| Only in SCBIHEALTH(E) | ||
 Gilead Sciences | 5.08% | N/A |
 Vertex Pharmaceuticals | 4.83% | N/A |
 Intuitive Surgical | 4.32% | N/A |
 Jazz Pharmaceuticals | 3.40% | N/A |
| Only in SCBRMGHC | ||
 Johnson & Johnson | N/A | 7.85% |
 Unitedhealth Group | N/A | 4.31% |
 Novartis | N/A | 2.76% |
 Roche | N/A | 2.70% |
30 Dec 2025 → 30 Oct 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| SCBIHEALTH(E) | +12.60% | 17.46% | 0.72 |
| SCBRMGHC | +10.74% | 16.87% | 0.64 |
| PCVX | +34.44% | 56.51% | 0.61 |
| DAOL-GIHEALTH | +0.59% | 18.60% | 0.03 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | PCVX | DAOL-GIHEALTH | SCBIHEALTH(E) | SCBRMGHC |
|---|---|---|---|---|
Fund details | ||||
| Fund size | N/A | 75.01 million | 30.55 million | 2,422 million |
| Inception date | N/A | 28 May 2020 | 29 Jun 2021 | 6 Nov 2015 |
| Master fund | N/A | Janus Henderson Horizon Biotechnology Fund | BNP Paribas Funds Health Care Innovators | Janus Henderson Global Life Sciences Fund |
| Dividend policy | N/A | Does not pay | Does not pay | Does not pay |
Risk and currency hedging | ||||
| Risk level | N/A | 7 | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Hedged at the manager's discretion | Almost fully hedged |
| Share hedged | N/A | 77.55% | 82.39% | 100.58% |
Minimum purchase and redemption | ||||
| First purchase | N/A | 1 THB | 1 THB | 1,000 THB |
| Subsequent purchase | N/A | 1 THB | 1 THB | 1,000 THB |
| Redemption (amount) | N/A | No minimum | 1 THB | 1,000 THB |
| Redemption (units) | N/A | No minimum | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | 1 THB | 1,000 THB |
| Balance (units) | N/A | 100 units | No minimum | No minimum |
Order cut-off and redemption payment | ||||
| Buy before | N/A | 15:00 | 15:30 | 15:30 |
| Redeem before | N/A | 15:00 | 15:30 | 15:30 |
| Redemption paid | N/A | T+4 | T+4 | T+5 |
